Article

Hypercalcaemia caused by a carcinoid tumour.

Department of Endocrinology, Waikato Hospital, Hamilton, New Zealand.
Internal Medicine Journal (impact factor: 1.54). 07/2009; 39(6):415-8. DOI:10.1111/j.1445-5994.2009.01934.x pp.415-8
Source: PubMed

ABSTRACT Humoral hypercalcaemia resulting from carcinoid tumours is uncommon. We report a case of hypercalcaemia because of excessive secretion of parathyroid hormone-related protein (PTHrP) in a 77-year-old woman with an advanced carcinoid tumour. Fibroblast growth factor 23 levels were also elevated. The hypercalcaemia responded to adjunctive therapy with long-acting octreotide analogue therapy, bisphosphonates and steroids. The role of PTHrP in humoral hypercalcaemia of malignancy, its association with neuroendocrine tumours, as well as the therapeutic use of somatostatin analogues are reviewed.

0 0
 · 
0 Bookmarks
 · 
37 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

77-year-old woman
 
advanced carcinoid tumour
 
bisphosphonates
 
carcinoid tumours
 
excessive secretion
 
Fibroblast growth factor 23 levels
 
humoral hypercalcaemia
 
hypercalcaemia
 
long-acting octreotide analogue therapy
 
neuroendocrine tumours
 
parathyroid hormone-related protein
 
somatostatin analogues
 
therapeutic use